Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (NCT03535298)

🧪 Interventions in This Study

• Early Highly Effective Therapies Group (DRUG)
• Escalation Therapies Group (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (30 Sites)

Showing the first 25 of 30 sites.

• University of Colorado-Anschutz Medical Campus — Aurora, Colorado
• University of Minnesota — Minneapolis, Minnesota
• Mayo Clinic — Rochester, Minnesota
• Cleveland Clinic Lou Ruvo Center for Brain Health — Las Vegas, Nevada
• University of Buffalo — Buffalo, New York
• University Rochester Medical Center — Rochester, New York
• University of Cincinnati — Cincinnati, Ohio
• Cleveland Clinic — Cleveland, Ohio
• Ohio Health — Columbus, Ohio
• UT-Austin — Austin, Texas
• Baylor College of Medicine, Houston — Houston, Texas
• UTHealth-Houston — Houston, Texas
• University of Virginia — Charlottesville, Virginia
• Virginia Commonwealth University — Richmond, Virginia
• University of Wisconsin-Madison — Madison, Wisconsin
• University Hospitals Coventry and Warwickshire — Coventry, England
• The Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary — Leeds, England
• University Hospitals Leicester — Leicester, England
• Imperial College Healthcare NHS Trust, Charing Cross Hospital — London, England
• University College London Hospitals NHS Foundation Trust, University College Hospital — London, England
• Salford Royal NHS Foundation Trust, Salford Hospital — Manchester, England
• Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital — Oxford, England
• University Hospitals Plymouth NHS Trust, Derriford Hospital — Plymouth, England
• Sheffield Teaching Hospitals — Sheffield, England
• University Hospitals of North Midlands — Stoke, England

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Sclerosis, Relapsing-Remitting

• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial — Birmingham, Alabama
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis — La Jolla, California
• Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis — Altamonte Springs, Florida
• A Post-Authorization, Long-term Study of Ozanimod Real-world Safety — Bethesda, Maryland
• Efficacy of Diet on Quality of Life in Multiple Sclerosis — Iowa City, Iowa

Explore by condition: All Multiple Sclerosis, Relapsing-Remitting clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.